Page last updated: 2024-08-24

plerixafor and Hematologic Diseases

plerixafor has been researched along with Hematologic Diseases in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (33.33)	29.6817
2010's	4 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anderson, KC; Armand, P; Azab, AK; Basile, F; Baz, R; Boruchov, A; Chuma, S; Constantine, M; Crilley, P; Ghobrial, IM; Henrick, PM; Hornburg, KTV; Laubach, JP; Leblebjian, H; Liu, CJ; Mishima, Y; Munshi, NC; Noonan, K; Paba-Prada, C; Reyes, K; Richardson, PG; Schlossman, R; Shain, K; Trippa, L; Vredenburgh, J; Warren, D; Weller, E; Zavidij, O	1
Altomare, L; Bertaina, A; Bertaina, V; Brescia, LP; Ceccarelli, S; Cefalo, MG; Conflitti, G; Corsetti, T; Filippini, P; Girolami, E; Li Pira, G; Locatelli, F; Lucarelli, B; Moretta, L; Rutella, S	1
Avecilla, S; Cushing, M; Mark, T; Pagan, C; Rhodes, J; Shore, T; Storch, E; van Besien, K	1
Greinix, HT; Worel, N	1
Bridger, G; Calandra, G; Fricker, S	1

Reviews

1 review(s) available for plerixafor and Hematologic Diseases

Article	Year
CXCR4 in clinical hematology. Current topics in microbiology and immunology, 2010, Volume: 341 Topics: Animals; Benzylamines; Clinical Trials as Topic; Cyclams; Drug Evaluation, Preclinical; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Receptors, CXCR4; Stem Cell Transplantation	2010

Trials

2 trial(s) available for plerixafor and Hematologic Diseases

Article	Year
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. American journal of hematology, 2019, Volume: 94, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylamines; Bone Marrow; Bortezomib; Combined Modality Therapy; Cyclams; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Receptors, CXCR4; Recurrence; Salvage Therapy; Tumor Microenvironment	2019
Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-αβ/CD19-depleted haploidentical stem cell grafts. Journal of translational medicine, 2014, Sep-02, Volume: 12 Topics: Allografts; Antigens, CD19; Antigens, CD34; Benzylamines; Blood Grouping and Crossmatching; Cell Count; Child; Cyclams; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Receptors, Antigen, T-Cell, alpha-beta; Tissue Donors	2014

Article

Year

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.

American journal of hematology, 2019, Volume: 94, Issue:11

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylamines; Bone Marrow; Bortezomib; Combined Modality Therapy; Cyclams; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Receptors, CXCR4; Recurrence; Salvage Therapy; Tumor Microenvironment

2019

Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-αβ/CD19-depleted haploidentical stem cell grafts.

Journal of translational medicine, 2014, Sep-02, Volume: 12

Topics: Allografts; Antigens, CD19; Antigens, CD34; Benzylamines; Blood Grouping and Crossmatching; Cell Count; Child; Cyclams; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Receptors, Antigen, T-Cell, alpha-beta; Tissue Donors

2014

Other Studies

3 other study(ies) available for plerixafor and Hematologic Diseases

Article	Year
A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration. Transfusion, 2015, Volume: 55, Issue:8 Topics: Adult; Aged; Algorithms; Antigens, CD34; Benzylamines; Blood Cell Count; Cell Separation; Clinical Protocols; Cyclams; Drug Synergism; Erythrocytes; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Testicular Neoplasms; Time Factors; Transplantation, Autologous; Young Adult	2015
New agents for mobilizing peripheral blood stem cells. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2009, Volume: 41, Issue:1 Topics: Benzylamines; Chemokine CXCL12; Cyclams; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Metabolism, Inborn Errors; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4	2009
Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791. Drugs in R&D, 2007, Volume: 8, Issue:2 Topics: Animals; Benzylamines; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclams; Hematologic Diseases; Heterocyclic Compounds; Mice; Neoplasms; Rats; Receptors, CXCR4; Stem Cells; Virus Diseases	2007